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Sir, 13
The emergence of carbapenemase-mediated resistance to all the β-lactam, including 14 the carbapenem is a major public health threat. In Enterobacteriaceae, one of the most 15 frequent carbapenemases is the Klebsiella pneumoniae carbapenemase (KPC) enzymes [1] [2] [3] . 16 Since the first KPC-producing isolate was identified from North Carolina, United States in 17 1996, occurrence of KPC-producing bacteria have been reported in other parts of the United 18
States, Europe, South America, the Middle East and Asia [1, 2] . In September 2010, Hong 19
Kong set up an enhanced surveillance system for detection of carbapenem-resistant 20 Enterobacteriaceae; following recent concerns that the transmission of these extensively 21 resistant organisms may be associated with medical tourism or surgery abroad in areas where 22 they are endemic [1] [2] [3] . In all the public hospitals, all newly admitted patients with potential 23 risk factors for carbapenem-resistant Enterobacteriaceae (e.g. overseas hospitalization) will 24 be actively screened for colonization. In clinical microbiology laboratories, all carbapenem-25 resistant Enterobacteriaceae isolates will be assessed for carbapenemase activity using 26 inhibition tests with boronic acid and ethylene diamine tetra-acetic acid (EDTA) [1] . Isolates 27 with positive carbapenemase screen test will be sent to the public health laboratory for 28 Solna, Sweden): meropenem (32 µg/ml, resistant), imipenem (32 µg/ml, resistant), 48 fosfomycin (24 µg/ml, sensitive) and colistin (0.38 µg/ml, sensitive). 49
The isolate was retrieved and tested for primers specific for the KPC genes. A positive 50 PCR result was obtained. Subsequent sequencing showed that a KPC-2 gene was carried by 51 the isolate. In order to identify the genetic background of this strain, the organism was 52 
